Cellomics and GE Healthcare sign licence agreements to expand availability of high content screening
Cellomics, the creator of high content screening (HCS), has entered into a non-exclusive, worldwide patent licence agreement for its core HCS patent portfolio with GE Healthcare (a combination of the former Amersham and GE Medical Systems).
In parallel, Cellomics and GE Healthcare have also entered into a limited term, exclusive agency agreement, which conveys to GE Healthcare rights to broker sublicences of Cellomics's HCS patent portfolio to key pharmaceutical companies.
"We are pleased to be working with GE Healthcare to broaden the availability of high content screening through the licensing of our HCS patent portfolio," commented Daniel Calvo, president and CEO of Cellomics.
"Further, we are delighted GE Healthcare will be assisting us in sublicensing HCS, helping to meet the needs of customers and expanding the availability of critical technologies such as HCS to a wider group of scientists".
"This relationship complements our strong portfolio of technologies for HCS.
"Moreover, it reinforces GE Healthcare's strategy of finding methods to help customers make informed decisions about progression through the drug development process," stated Michael Evans, VP marketing and strategy, discovery systems.
"These agreements with Cellomics help us to enable customers to ask complex biological questions using our cellular sensors and, in turn, interpret the answers".
Cellomics has more than 30 issued or allowed patents and an additional 30 patents pending in the field of HCS.
The company's global patent portfolio includes both broad claims to HCS technology as well as specific classes of HCS assays such as cytoplasm-nuclear translocation, characterisation of cellular toxicity, and receptor internalisation. "Cellomics developed a very strong intellectual property portfolio, while creating the market and products for HCS", added Lansing Taylor, founder and Cellomics board member.
With nearly a decade of experience in developing and commercialising automated high content cell analysis solutions for drug discovery, and the largest user base behind it, Cellomics continues to develop complete solutions for drug discovery as well as life science researchers.
"Through our internal product development we have had a long history of providing tools for high content biological analyses," continued Calvo. "To complement our own product development, we have partnered with other companies on synergistic product solutions. "Now, in actively licensing our intellectual property, we are continuing to respond to and meet the needs of our customers, which will ultimately accelerate the availability of HCS technologies for all scientists."
